查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1896974

全球无菌检测市场：依产品、检测方法、应用、最终用户及地区划分－市场规模、产业动态、机会分析及预测（2026-2035 年）

Global Sterility Testing Market: By Products, Test, Application, End Users, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 210 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

无菌检测市场持续强劲稳定成长，预计到 2025 年将达到约 13.3431 亿美元。这一成长趋势预计将在未来十年持续，到 2035 年将达到约 39.1335 亿美元。这一显着增长意味着 2026 年至 2035 年的复合年增长率 (CAGR) 为 11.36%。

推动市场扩张的主要因素之一是药品生产监管环境的严格性。包括 FDA 和 EMA 在内的全球监管机构制定了严格的标准和指南，以确保无菌产品完全不含微生物污染。这些法规要求采用全面的无菌检测方案，迫使製造商实施先进的检测技术并维持严格的品质控制系统。

市场趋势展望

全球无菌检测市场的竞争格局正日益受到积极采用自动化和数位化技术以简化检测流程的公司的影响。这些技术进步使得无菌检测流程更加快速、准确和高效，这对于满足製药和生物製药行业严格的品质标准至关重要。

这一趋势的一个显着例证是，领先的合约研发生产机构 (CDMO) Recipharm 于 2025 年 10 月在其位于印度班加罗尔的工厂开设了一家新的注射剂研发和无菌检测实验室。此次扩建体现了该公司致力于透过引入先进技术和专业基础设施来增强其服务能力，从而支援复杂的无菌产品研发。

大约在同一时间，即2025年10月30日，Avantron推出了其新一代无菌取样平台和预製PUPSIT（产品单元灭菌前完整性测试）组件。这些创新技术旨在简化生物製程验证流程，并在生产过程中实现更明智的即时决策。同月，Sotera Health旗下子公司Nelson Labs推出了RapidCert。 Nelson Labs是医疗器材和製药业领先的外包微生物和分析化学检测服务提供者。这项新型快速生物指示剂（RBI）无菌检测服务结合了传统生物指示剂（BI）和快速微生物方法（RMM），可提供快速可靠的无菌检测结果。

核心成长驱动因子

在製药和生物製药行业，无菌检测是生产过程中每个阶段都必须执行的重要流程，旨在最大限度地降低产品污染的风险。 在研发、生产和包装过程中保持产品无菌状态对于确保病患安全和符合法规要求至关重要。这种全面的无菌检测方法包括严格的监测和控制措施，以检测和消除可能损害产品品质的微生物污染。由于药品和生物製药（尤其是生物製剂和无菌注射剂）的复杂性和敏感性，在整个生产过程中持续进行无菌检测对于保护这些治疗药物的完整性至关重要。

新兴机会

无菌检测和颗粒检测的日益融合是塑造无菌检测市场的关键趋势。这项发展主要源自于人们对药品中异物颗粒污染风险的认识不断提高。到2024年，约20%的产品召回将由外来物颗粒引起，这凸显了全面品质保证措施的迫切需求，这些措施应同时解决微生物污染和颗粒物污染问题。因此，客户现在正在寻求更精简、更有效率的检测解决方案，将这些必要的检测整合到一个统一的服务中。

优化障碍

目前，无菌检测市场面临严重的人才短缺，这对市场成长和营运效率构成了重大挑战。随着业界向快速检测方法和复杂生物製剂的开发方向发展，对具备验证流程专业知识的微生物学家的需求激增。这些先进的检测技术和复杂的产品需要专业人员不仅要对微生物学原理有深刻的理解，还要具备严格的验证方案的实务经验，以确保准确性和合规性。在创新技术不断补充或取代传统方法的环境下，这种专业技能对于维持最高的无菌保证标准至关重要。

目录

第一章：摘要整理：全球无菌检测市场

第二章：研究方法与架构

  • 研究目标
  • 产品概述
  • 市场区隔
  • 质性研究
    • 一级和二级皮革类型
  • 量化研究
    • 一级和二级皮革类型
  • 按地区划分的一级调查受访者
  • 研究假设
  • 市场规模估算
  • 资料三角验证

第三章：全球无菌检测市场概况

  • 产业价值链分析
    • 原料供应商
    • 製造商
    • 经销商
    • 服务提供者
    • 最终用户
  • 行业展望
    • 研发支出（占GDP的百分比）
    • 2024年十大製药公司研发预算
    • 个案研究分析：
  • PESTLE分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场成长与展望
    • 市场收入估计与预测（2020-2035）
    • 价格趋势分析（按基材）
  • 市场吸引力分析
    • 依基材划分
    • 按地区划分
  • 可操作的洞见（分析师建议）

第四章：竞争格局概览

  • 市场集中度
  • 公司市占率分析（按价值，2025 年）
  • 竞争格局分析与基准分析

第五章：全球无菌检测市场分析

  • 市场动态与趋势
    • 成长驱动因素
    • 限制因素
    • 机遇
    • 主要趋势
  • 市场规模及预测（2020-2035 年）
    • 按测试
      • 薄膜过滤
      • 直接转移
      • 产品冲洗
    • 依产品分类
      • 试剂盒
      • 服务
      • 设备
    • 依应用程式分类
      • 医疗器材
      • 药品
      • 其他
    • 依最终使用者分类
      • 医院和诊所
      • 製药公司
      • 研究实验室
      • 其他
    • 依地区分类

第六章：北美无菌检测市场分析

第七章：欧洲无菌检测市场分析

第八章：亚太地区无菌检测市场分析

第九章：中东与非洲无菌检测市场分析

第十章：南美洲无菌检测市场分析

第十一章：公司简介

  • 赛默飞世尔科技公司 (Thermo Fisher Scientific Inc.)
  • 查尔斯河实验室国际公司 (Charles River Laboratories International, Inc.)
  • 赛多利斯股份公司 (Sartorius AG)
  • SGS集团
  • 生物梅里埃公司 (bioMerieux SA)
  • 欧陆科技 (Eurofins Scientific)
  • 阿尔卡米公司 (Alcami Corporation)
  • 斯特里斯公司 (Steris plc)
  • 佩斯分析公司 (Pace analytical)
  • 纳尔逊实验室有限责任公司 (Nelson Laboratories, LLC) - 索特拉健康公司 (Sotera Health company)
  • 维罗西有限公司 (Viroxy Sdn. Bhd.) Bhd
  • Pacific BioLabs, Inc.
  • 药明康德
  • Bioquell（艺康解决方案）
  • 默克
  • 其他主要参与者

第十二章附录

简介目录
Product Code: AA1024945

The sterility testing market is witnessing robust and steady growth, with its valuation reaching approximately US$ 1,334.31 million in 2025. This upward trajectory is expected to continue throughout the coming decade, projecting the market to achieve a valuation of around US$ 3,913.35 million by 2035. This significant expansion corresponds to a compound annual growth rate (CAGR) of 11.36% during the forecast period from 2026 to 2035.

One of the primary drivers fueling this market expansion is the stringent regulatory environment governing pharmaceutical manufacturing. Regulatory agencies worldwide, including the FDA, EMA, and others, impose rigorous standards and guidelines to ensure that sterile products are free from microbial contamination. These regulations necessitate comprehensive sterility testing protocols, compelling manufacturers to adopt advanced testing technologies and maintain stringent quality control systems.

Noteworthy Market Developments

The competitive landscape of the global sterility testing market is increasingly shaped by companies that have successfully embraced automation and digitalization to enhance their testing workflows. These technological advancements enable faster, more accurate, and more efficient sterility testing processes, which are critical in meeting the demanding quality standards of the pharmaceutical and biopharmaceutical industries.

A notable example of this trend occurred in October 2025, when Recipharm, a leading contract development and manufacturing organization (CDMO), inaugurated its newly commissioned parenteral development and sterility testing laboratories at its Bengaluru facility in India. This expansion reflects Recipharm's commitment to enhancing its service capabilities by incorporating advanced technologies and specialized infrastructure to support complex sterile product development.

Around the same time, Avantoron introduced a next-generation sterile sampling platform alongside pre-engineered PUPSIT (Product Unit Pre-sterilization Integrity Test) assemblies on October 30, 2025. These innovations are aimed at streamlining bioprocessing qualification and enabling more informed, real-time decision-making during manufacturing. In the same month, Nelson Labs, a subsidiary of Sotera Health and a prominent provider of outsourced microbiological and analytical chemistry testing services for the medical device and pharmaceutical industries, launched RapidCert. This new rapid biological indicator (RBI) sterility service combines traditional biological indicators (BIs) with rapid microbiological methods (RMMs) to deliver expedited and reliable sterility testing results.

Core Growth Drivers

In the pharmaceutical and biopharmaceutical industries, sterility testing is an indispensable process conducted at every stage of manufacturing to minimize the risk of product contamination. Ensuring that products remain sterile throughout development, production, and packaging is critical for maintaining patient safety and regulatory compliance. This comprehensive approach to sterility testing involves rigorous monitoring and control measures designed to detect and eliminate any potential microbial contamination that could compromise product quality. Given the complexity and sensitivity of pharmaceutical and biopharmaceutical products, particularly biologics and sterile injectables, consistent sterility testing throughout the manufacturing pipeline is essential to safeguard the integrity of these therapies.

Emerging Opportunity Trends

A significant trend shaping the sterility testing market is the growing integration of sterility testing with particulate testing. This development is largely driven by the increasing awareness of the risks posed by foreign material contamination in pharmaceutical products. In 2024, approximately 20% of product recalls were attributed to the presence of foreign particles, highlighting the critical need for comprehensive quality assurance measures that address both microbial contamination and particulate matter. As a result, customers are now seeking more streamlined and efficient testing solutions that combine these essential inspections into a single, cohesive service offering.

Barriers to Optimization

The sterility testing market is currently grappling with a significant talent shortage, which poses a serious challenge to its growth and operational efficiency. As the industry increasingly shifts towards rapid testing methods and the development of complex biologics, the demand for microbiologists with specialized expertise in validation processes has surged. These advanced testing technologies and sophisticated products require professionals who not only have a deep understanding of microbiological principles but also possess hands-on experience with stringent validation protocols to ensure accuracy and compliance. This specialized skill set is essential to maintaining the highest standards of sterility assurance in an environment where traditional methods are being supplemented or replaced by innovative techniques.

Detailed Market Segmentation

Based on test type, the membrane filtration test currently holds a leading position in the sterility testing market, contributing over 46.1% of the total revenue. This prominent standing is largely due to its recognition as the pharmacopeial gold standard for sterility testing, especially when it comes to filterable pharmaceutical products. Membrane filtration is widely preferred in the industry because it allows for the effective separation and retention of microorganisms on a filter, enabling precise detection of potential contaminants. Its ability to handle large volumes of liquid samples makes it particularly suitable for products that require rinsing steps to eliminate antimicrobial agents that could otherwise interfere with the accuracy of sterility results.

Based on product type, sterility testing kits currently lead the sterility testing market, accounting for more than 49.0% of the total market share. This dominant position reflects the growing preference within the pharmaceutical and biopharmaceutical industries for consumable-based testing solutions. Sterility testing kits offer a convenient and standardized approach to detecting microbial contamination, making them integral to quality control processes. Their widespread adoption is fueled by the increasing emphasis on ensuring product safety while optimizing operational efficiency in manufacturing environments.

Based on end users, pharmaceutical companies occupy a leading position in the sterility testing market, commanding over 44.3% of the total market share. This dominance is driven by the critical role these companies play in ensuring the safety and efficacy of their products before they reach consumers. As the ultimate custodians of patient health, pharmaceutical manufacturers bear the responsibility for comprehensive quality assurance, which includes rigorous sterility testing of their products. Their commitment to maintaining high standards compels them to invest substantially in robust internal quality control systems to monitor and verify the sterility of every batch produced.

Based on application, sterility testing is predominantly utilized in the inspection of pharmaceutical products, representing a significant portion of the overall market. This application segment commands over 42.2% of the market share, highlighting its critical importance within the sterility testing landscape. The primary reason for this substantial share lies in the stringent regulatory requirements that mandate every batch of sterile pharmaceutical formulations to undergo comprehensive release testing before they can be distributed to patients.

Segment Breakdown

By Product

  • Kits
  • Services
  • Instruments

By Test

  • Membrane Filtration
  • Direct Transfer
  • Product Flush

By Application

  • Medical Devices
  • Pharmaceutical products
  • Other applications

By End User

  • Hospitals & Clinics
  • Pharmaceutical Companies
  • Research Laboratories
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a commanding position in the global sterility testing market, controlling approximately 50.2% of the market share. This dominant stance is largely attributed to the region's aggressive upgrades in pharmaceutical infrastructure, which have significantly enhanced its capacity for sterility testing. The United States, in particular, plays a pivotal role due to the presence of numerous global pharmaceutical and biopharmaceutical companies, coupled with substantial funding from both government and private sectors dedicated to research and development.
  • The regulatory landscape in North America further strengthens its market dominance. Regulatory bodies in the region actively promote innovation while enforcing stringent quality and safety standards, which drives the demand for advanced sterility testing services. This regulatory environment ensures that pharmaceutical products meet rigorous sterility requirements, thereby safeguarding public health and boosting confidence in the market.

Leading Market Participants

  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories International, Inc
  • Sartorius AG
  • SGS S.A.
  • bioMerieux SA
  • Eurofins Scientific
  • Alcami Corporation
  • Steris plc
  • Pace analytical
  • Nelson Laboratories, LLC - A Sotera Health company
  • Viroxy Sdn. Bhd
  • Pacific BioLabs, Inc.
  • WuXi AppTec
  • Bioquell (Ecolab Solution)
  • Merck
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Sterility Testing Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Leather Types
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Leather Types
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Sterility Testing Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Provider
    • 3.1.2. Manufacturer
    • 3.1.3. Distributor
    • 3.1.4. Service Provider
    • 3.1.5. End User
  • 3.2. Industry Outlook
    • 3.2.1. Research and development expenditure (% of GDP)
    • 3.2.2. Top 10 Pharma R&D Budgets in 2024
    • 3.2.3. Case Study Analysis:
      • 3.2.3.1. Performance Survey and Comparison Between Rapid Sterility Testing Method and Pharmacopoeia Sterility Test
      • 3.2.3.2. Sterility Testing of Pharmaceuticals
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Base Material
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Base Material
    • 3.6.2. By Region
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Sterility Testing Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Test
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Membrane Filtration
        • 5.2.1.1.2. Direct Transfer
        • 5.2.1.1.3. Product Flush
    • 5.2.2. By Product Type
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Instruments
        • 5.2.2.1.2. Kits & Reagents
        • 5.2.2.1.3. Services
    • 5.2.3. By Application
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Medical Devices
        • 5.2.3.1.2. Pharmaceutical Products
        • 5.2.3.1.3. Others
    • 5.2.4. By End User
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Hospitals & Clinics
        • 5.2.4.1.2. Pharmaceutical Companies
        • 5.2.4.1.3. Research Laboratories
        • 5.2.4.1.4. Others
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. South Korea
          • 5.2.5.1.3.5. Australia & New Zealand
          • 5.2.5.1.3.6. ASEAN
              • 5.2.5.1.3.6.1.1. Indonesia
              • 5.2.5.1.3.6.1.2. Malaysia
              • 5.2.5.1.3.6.1.3. Thailand
              • 5.2.5.1.3.6.1.4. Singapore
              • 5.2.5.1.3.6.1.5. Rest of ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa
          • 5.2.5.1.4.1. UAE
          • 5.2.5.1.4.2. Saudi Arabia
          • 5.2.5.1.4.3. South Africa
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Sterility Testing Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Test
    • 6.2.2. By Product Type
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country

Chapter 7. Europe Sterility Testing Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Test
    • 7.2.2. By Product Type
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country

Chapter 8. Asia Pacific Sterility Testing Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Test
    • 8.2.2. By Product Type
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country

Chapter 9. Middle East & Africa Sterility Testing Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Test
    • 9.2.2. By Product Type
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country

Chapter 10. South America Sterility Testing Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Test
    • 10.2.2. By Product Type
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Thermo Fisher Scientific Inc.
  • 11.2. Charles River Laboratories International, Inc
  • 11.3. Sartorius AG
  • 11.4. SGS S.A.
  • 11.5. bioMerieux SA
  • 11.6. Eurofins Scientific
  • 11.7. Alcami Corporation
  • 11.8. Steris plc
  • 11.9. Pace analytical
  • 11.10. Nelson Laboratories, LLC - A Sotera Health company
  • 11.11. Viroxy Sdn. Bhd
  • 11.12. Pacific BioLabs, Inc.
  • 11.13. WuXi AppTec
  • 11.14. Bioquell (Ecolab Solution)
  • 11.15. Merck
  • 11.16. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Leather Types
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators